Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridLaktionov, Konstantin K/0000-0003-4469-502X;
dc.authorwosidnovello, silvia/K-6335-2016
dc.authorwosidPaz-Ares, Luis/AAH-2750-2019
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidLaktionov, Konstantin K/G-1431-2019
dc.authorwosidMAZIERES, JULIEN/M-3986-2014
dc.authorwosidGumus, Mahmut/C-7135-2008
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.contributor.authorMazieres, J.
dc.contributor.authorKowalski, D.
dc.contributor.authorLuft, A.
dc.contributor.authorVicente, D.
dc.contributor.authorTafreshi, A.
dc.contributor.authorGumus, M.
dc.contributor.authorLaktionov, K.
dc.date.accessioned2024-06-12T11:24:06Z
dc.date.available2024-06-12T11:24:06Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANYen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncolen_US
dc.description.sponsorshipMerck Sharp & Dohme Corp., of Merck & Co., Inc., Kenilworth, NJ, USAen_US
dc.description.sponsorshipThis research was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26797
dc.identifier.volume29en_US
dc.identifier.wosWOS:000459277305011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleHealth-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu